Charles Flexner

The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

National Institute of Allergy and Infectious Diseases · R24

Contact PI · $9.4M · Johns Hopkins University

Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)

National Institute of Allergy and Infectious Diseases · UM1

Contact PI · $34.1M · Johns Hopkins University

Johns Hopkins AIDS Clinical Trials Unit

National Institute of Allergy and Infectious Diseases · U01

Contact PI · $7.9M · Johns Hopkins University

General Clinical Research Center

National Center for Research Resources · M01

Project lead · $1.3M · Johns Hopkins University

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

Study chair · Completed · Phase 1

National Institute of Allergy and Infectious Diseases (NIAID)

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

Study chair · Completed · Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)

Menopausal HT for Women Living With HIV (HoT)

Site PI · Recruiting · Phase 4

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections